HARMONY BIOSCIENCES HOLDINGS INCORPORATED (HRMY)

Hedge funds and other institutional investors own 86.23% of the company’s stock. Shares of HRMY opened at $35.86 on Friday. The company has a market cap of $2.08 billion, a price-to-earnings ratio of 14.46, a price-to-earnings-growth ratio of 0.33 and a beta of 0.94.

Some better-ranked stocks in the ... HRMY, Kiniksa Pharmaceuticals KNSA and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Over the past 60 days, estimates for Harmony Biosciences' 2026 earnings per…

This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ACAD currently has a PEG ratio of 18.26. Another notable valuation metric for HRMY is its P/B ratio of 2.28. Investors use the P/B ratio to look at a stock's market …

Some better-ranked stocks in the ... HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy) and Neurocrine Biosciences NBIX which carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Over the past 90 days, earnings per s…

These figures are just a handful of the metrics value investors tend to look at, but they help show that Harmony Biosciences is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, HRMY feels like a great value stock at the moment.